Thyrocare Q4FY25 Revenue Up 21 Percent YoY to Rs 187.2 Cr; PAT Rises 24 Percent to Rs 21.3 Cr
Navi Mumbai (Maharashtra) [India], April 24: Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended March 31, 2025. For Q4FY25, the company reported revenue from operations of INR 187.2 crore, reflecting a 21% year-over-year (YoY) growth. Normalized EBITDA for the quarter stood at INR 65.3 crore, marking a robust 78% YoY increase. Profit after tax (PAT), excluding exceptional items, reached INR 32.5 crore, which represents an impressive 88% YoY growth.Thyrocare Technologies Limited Key highlights for Q4FY25: Consolidated revenue increased by 21% year-over-year (YoY) with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively Total volum
Read More